TriNetX, Inc. acquires Custodix NV
The acquisition creates the largest clinical research network in the world, covering the US, Europe, Asia and South America.
TriNetX, Inc. (MA, USA) has acquired Custodix NV (Belgium) for an undisclosed fee, establishing the largest research network in the world. TriNetX, a health research network that generates real-world evidence (RWE) across Japan, Singapore, Phillipines, India, Israel and Brazil, provides TriNetX with a foothold in the EU with a view to further expansion. It also provides customers of Custodix’s InSite network with increased access to clinical trial opportunities outside of Europe.
“This is a breathtaking unification of two extremely compatible research networks,” said Gadi Lachman, TriNetX CEO. “The two companies launched in separate geographies, but share a commitment to strong compliance, governance, and a global vision for clinical research. We now offer the world’s largest platform for clinical research, providing a more powerful resource for pharma companies and healthcare organizations, and more hope for patients in need. This expansion gives us additional local leadership, regional support, and increased resources in the European market.”
Custodix, which provides services for clinical trial design, patient feasibility and patient recruitment, received the 2018 Clinical Informatics News European Innovation Award for the InSite platform, which was also named one of the most promising SME health initiatives in 2016 by the European Commission. The financial details of the acquisition have not been disclosed.
“This deal is exciting news for the healthcare organizations in our InSite network,” said Brecht Claerhout, CEO, Custodix. “We share similar values to TriNetX, which will enable us to continue collaborating with the hospital community, service our customer base as we always have, and bring new clinical trial opportunities to researchers and their patients.”